Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance



: Nevo J, Mattila E, Pellinen T, Yamamoto DL, Sara H, Iljin K, Kallioniemi O, Bono P, Heikkila P, Joensuu H, Warri A, Ivaska J

Publisher: AMER ASSOC CANCER RESEARCH

: 2009

: Clinical Cancer Research

: CLINICAL CANCER RESEARCH

: CLIN CANCER RES

: 15

: 21

: 6570

: 6581

: 12

: 1078-0432

DOI: https://doi.org/10.1158/1078-0432.CCR-09-0773(external)


Conclusions: MDGI-driven inherent desensitization of cancer cells is a novel molecular mechanism for resistance to the anti-EGFR antibody therapy, and MDGI may be a biomarker for responsiveness to anti-EGFR antibody therapy. (Clin Cancer Res 2009;15(21):6570-81)



Last updated on 2024-26-11 at 14:37